Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer

BACKGROUND: Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lheureux, Stephanie, Matei, Daniela E, Konstantinopoulos, Panagiotis A, Wang, Ben X, Gadalla, Ramy, Block, Matthew S, Jewell, Andrea, Gaillard, Stephanie L, McHale, Michael, McCourt, Carolyn, Temkin, Sarah, Girda, Eugenia, Backes, Floor J, Werner, Theresa L, Duska, Linda, Kehoe, Siobhan, Colombo, Ilaria, Wang, Lisa, Li, Xuan, Wildman, Rachel, Soleimani, Shirin, Lien, Scott, Wright, John, Pugh, Trevor, Ohashi, Pamela S, Brooks, David G, Fleming, Gini F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921950/
https://www.ncbi.nlm.nih.gov/pubmed/35288469
http://dx.doi.org/10.1136/jitc-2021-004233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921950/
https://www.ncbi.nlm.nih.gov/pubmed/35288469
http://dx.doi.org/10.1136/jitc-2021-004233

Ejemplares similares